ArticleAntimicrobial agents and chemotherapy2006
Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Antifungal pharmacodynamics: Latin America's perspective.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesPooled it
- Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants.The Journal of antimicrobial chemotherapy · 2018Trial
- Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Antimicrobial agents and chemotherapy · 2015Trial
- Irrational and Inappropriate Use of Antifungals in the NICU: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Predicted no effect concentrations of antifungals for wastewater management and agricultural use.Frontiers in toxicology · 2026Review
- The prevalence, patterns, and antifungal drug resistance of bloodstream infection-causing fungi in Sichuan Province, China (2019-2023): a retrospective observational study using national monitoring data.Frontiers in microbiology · 2025Article
- Unlocking the potential of experimental evolution to study drug resistance in pathogenic fungi.npj antimicrobials and resistance · 2024Review
- Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Therapeutic drug monitoring of mycophenolic acid and azole antifungals on two distinct LC-MS/MS instruments.Journal of mass spectrometry and advances in the clinical lab · 2024Article
- Validation Study of a Clinical Predictive Model for Fluconazole Resistance in Patients WithOpen forum infectious diseases · 2023Article
- Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?Infectious diseases and therapy · 2020Article
- Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.PLoS neglected tropical diseases · 2019Article
- Microevolution of the pathogenic yeastsMicrobial cell (Graz, Austria) · 2019Review
- Review
- Strong Synergism of Palmatine and Fluconazole/Itraconazole Against Planktonic and Biofilm Cells ofFrontiers in microbiology · 2018Article
- Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains.Antimicrobial agents and chemotherapy · 2017Article
- Modeling the growth dynamics of multiple Escherichia coli strains in the pig intestine following intramuscular ampicillin treatment.BMC microbiology · 2016Article
- The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen.Journal of microbiology (Seoul, Korea) · 2016Review
- Pharmacodynamic modelling of in vitro activity of tetracycline against a representative, naturally occurring population of porcine Escherichia coli.Acta veterinaria Scandinavica · 2015Article
- Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.Intensive care medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Numerous factors have been theorized to affect the development of antimicrobial resistance, including those specific to the host, the organism, the environment, the drug, and the drug prescriber. One variable under the control of the prescriber is the drug dosing regimen. Dosing regimens can vary in dose level, dosing interval, and treatment duration. The current studies examined the relationships between antimicrobial dosing regimens and resistance development by use of an in vivo model. A murine model of systemic Candida albicans infection was used to examine resistance emergence during exposure to the triazole antifungal fluconazole. Data from this experimental model demonstrated that the more frequently administered dosing prevented selection of the isogenic resistant cell populations. Conversely, dosing regimens producing prolonged sub-MIC effects appeared to contribute to the outgrowth of isogenic resistant strains. The association between dosing and resistance emergence observed in the current investigation is disparate from that described for antimicrobial compounds with cidal killing characteristics. The inhibitory or static antimicrobial activity of the triazole compounds may explain these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.